Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 77-88

  Gakhar, Gunjan ^a   Hua, Duy H ^a   Nguyen, Thu Annelise ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Breast cancer; Caspases; Gap junctional activator; PQ1; Tamoxifen

Indexed keywords

CASPASE 3; CYCLIN D1; KI 67 ANTIGEN; PQ 1; PROTEIN BAX; QUINOLINE DERIVATIVE; SURVIVIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; GAP JUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GAP JUNCTIONS; HUMANS; KI-67 ANTIGEN; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MICROTUBULE-ASSOCIATED PROTEINS; QUINOLINES; TAMOXIFEN;

EID: 74349092183     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328333d557     Document Type: Article

References (52)

1. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53:25-71. (Pubitemid 32173107)
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618.
3. Berstein LM, Zheng H, Yue W, Wang JP, Lykkesfeldt AE, Naftolin F, et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003; 10:267-277.
4. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007; 256:1-24.
5. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, et al. ERR gamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 2008; 68:8908-8917.
6. Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43:413-416.
7. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26:237-246.
8. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8:1005-1018.
9. Goldhirsch A, Gelber RD. Adjuvant therapy of primary breast cancer. In: Senn H-J, Goldhirsch A, Gelber RD, Osterwalder B, editors. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients. Ludwig studies III & IV, New York: Springer-Verlag; 1989. pp. 153-162.
10. Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol 1988; 27:699-705.
11. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2078-2085.
12. Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 1997; 15:2302-2311.
13. Group TIBCS. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15:1385-1394.
14. Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V. Connexins and their channels in cell growth and cell death. Cell Signal 2006; 18:592-600.
15. Krutovskikh VA, Piccoli C, Yamasaki H. Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 2002; 21:1989-1999.
16. Goodall H, Maro B. Major loss of junctional coupling during mitosis in early mouse embryos. J Cell Biol 1986; 102:568-575.
17. O'Lague P, Dalen H, Rubin H, Tobias C. Electrical coupling: Low resistance junctions between mitotic and interphase fibroblasts in tissue culture. Science 1970; 170:464-466.
18. Stein LS, Boonstra J, Burghardt RC. Reduced cell-cell communication between mitotic and nonmitotic coupled cells. Exp Cell Res 1992; 198:1-7.
19. Trosko JE, Chang CC. Potential role of intercellular communication in the rate-limiting step in carcinogenesis. J Am Coll Toxicol 1983; 2:5-22.
20. Murray AW, Fitzgerald DJ. Tumor promoters inhibit metabolic cooperation in cocultures of epidermal and 3T3 cells. Biochem Biophys Res Commun 1979; 91:395-401.
21. Yotti LP, Chang CC, Trosko JE. Elimination of metabolic cooperation in Chinese hamster cells by a tumor promoter. Science 1979; 206:1089-1091.
22. Enomoto T, Sasaki Y, Shiba Y, Kanno Y, Yamasaki H. Tumor promoters cause a rapid and reversible inhibition of the formation and maintenance of electrical cell coupling in culture. Proc Natl Acad Sci 1981; 78:5628-5632. (Pubitemid 12245203)
23. Sugie S, Mori H, Takahashi M. Effect of in vivo exposure to the liver tumor promoters phenobarbital or DDT on the gap junctions of rat hepatocytes: a quantitative freeze-fracture analysis. Carcinogenesis 1987; 8:45-51.
24. Mesnil M, Fitzgerald DJ, Yamasaki H. Phenobarbital specifically reduces gap junction protein mRNA level in rat liver. Mol Carcinog 1988; 1:79-81.
25. Fitzgerald DJ, Mesnil M, Oyamada M, Tsuda H, Ito N, Yamasaki H. Changes in gap junction protein (connexin 32) gene expression during rat liver carcinogenesis. J Cell Biochem 1989; 41:97-102.
26. Neveu MJ Hully JR, Paul DL, Pitot HC. Regulation of the expression of protooncogenes and the gene of the 27-KD gap junction protein during multistage hepatocarcinogenesis in the rat. Proc Am Assoc Cancer Res 1989; 30:207.
27. Gakhar G, Ohira T, Shi A, Hua DH, Nguyen TA. Antitumor effect of substituted quinolines in breast cancer cells. Drug Develop Res 69:526-534.
28. Osborne C, Elledge RM, Fuqua SAW. Estrogen receptors in breast cancer therapy. Sci Med 1996; 3:32-41.
29. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997; 72:608-613.
30. Langan FSM, Jordan VC, Fritz NF, Robinson SP,Waters D, Tormey DC. Long term tamoxifen treatment for breast cancer. In: Jordan VC, editor. Clinical pharmacology and endocrinology of long-term tamoxifen therapy. Madison: The University of Wisconsin Press; 1994. pp. 27-56.
31. Leshchenko Y, Likhodii S, Yue W, Burnham WM, Perez Velazquez JL. Carbenoxolone does not cross the blood brain barrier: an HPLC study. BMC Neurosci 2006; 7:3.
32. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6:469-477.
33. Gelmann EP. Tamoxifen induction of apoptosis in estrogen receptornegative cancers: new tricks for an old dog? J Natl Cancer Inst 1996; 88:224-226.
34. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995; 2:238-245.
35. Martin G, Melito G, Rivera E, Levin E, Davio C, Cricco G, et al. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors. Cancer Lett 1996; 100:227-234.
36. Group TBIGBI-C. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
37. Land SR,Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2742-2751.
38. Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, et al. Tamoxifen-induced apoptosis in breast cancer cells relates to downregulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res 1999; 5:2971-2977.
39. Mandlekar S, Yu R, Tan TH, Kong AN. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 2000; 60:5995-6000.
40. Tehrani FK, Salami S. Cell kinetic study of tamoxifen treated MCF-7 and MDA-MB 468 breast cancer cell lines. Iran Biomed J 2003; 7:51-56.
41. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1993; 67: 606-611.
42. Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, et al. The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 1998; 273:6110-6120.
43. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005; 11:3155-3162.
44. Zhang A, Wu Y, Lai HWL, Yew DT. Apoptosis-A brief review. Neuroembryology 2004; 3:47-59.
45. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003; 5:447-452.
46. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14:85-90.
47. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580-584.
48. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci 2008; 99:1709-1714.
49. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008; 26:59-65.
50. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
51. Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC, et al. The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer 2006; 5:7.
52. Jensen R, Glazer PM. Cell-interdependent cisplatin killing by Ku/DNAdependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci 2004; 101:6134-6139.